Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma

American Journal of Clinical Pathology

Volumn 127, Issue 5, 2007, Pages 780-786

  Peiró, Gloria ^a   Adrover, Encarna ^a   Aranda, Francisco I ^a   Peiró, Francisca M ^a   Niveiro, Maria ^a   Sánchez Payá, José ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Breast carcinoma; Estrogen receptor; HER 2; Progesterone receptor; Prognosis

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BREAST TUMOR; CHEMISTRY; FEMALE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 34249727189     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/FWHEQX6HB9190LVY     Document Type: Article

References (33)

1. Mirza AN, Mirza NQ, Vlastos G, et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 2002;235:10-26.
2. Wiebe JP, Lewis MJ, Cialacu V, et al. The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics. J Steroid Biochem Mol Biol. 2005;93:201-208.
3. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol. 2000;20:5041-5047.
4. Ronski K, Sanders M, Burleson JA, et al. Early growth response gene 1 (EGR1) is deleted in estrogen receptor - negative human breast carcinoma. Cancer. 2005;104:925-930.
5. Kamali-Sarvestani E, Gharesi-Fard B, Sarvari J, et al. Association of TNF-alpha and TNF-beta gene polymorphism with steroid receptor expression in breast cancer patients. Pathol Oncol Res. 2005;11:99-102.
6. Lee WY, Chen HH, Chow NH, et al. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res. 2005;11:2222-2228.
7. Boonyaratanakornkit V, Scott MP, Ribon V, et al. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell. 2001;8:269-280.
8. Zarubin T, Jing Q, New L, et al. Identification of eight genes that are potentially involved in tamoxifen sensitivity in breast cancer cells. Cell Res. 2005;15:439-446.
9. Clarke R, Liu MC, Bouker KB, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003;22:7316-7339.
10. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998;51:227-238.
11. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
12. Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17:1974-1982.
13. Kakar S, Puangsuvan N, Stevens JM, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000;5:199-207.
14. Lebeau A, Deimling D, Kaltz C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001;19:354-363.
15. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290-297.
16. Pinto AE, Andre S, Pereira T, et al. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol. 2001;12:525-533.
17. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res. 2001;61:5345-5348.
18. Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol. 2002;79:216-223.
19. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001;61(suppl 2):1-13.
20. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003;9:923-930.
21. Volpi A, Nanni O, De Paola F, et al. HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol. 2003;21:2708-2712.
22. Pellikainen J, Naukkarinen A, Ropponen K, et al. Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer. 2004;40:1485-1495.
23. Dandachi N, Dietze O, Hauser-Kronberger C. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer. Anticancer Res. 2004;24:2401-2406.
24. Grann VR, Troxel AB, Zojwalla NJ, et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005;103:2241-2251.
25. Jukkola A, Bloigu R, Soini Y, et al. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer. 2001;37:347-354.
26. Ropero S, Menendez JA, Vazquez-Martin A, et al. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat. 2004;86:125-137.
27. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
28. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000;157:1467-1472.
29. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor - positive primary breast cancer. J Natl Cancer Inst. 2003;95:142-153.
30. Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995;13:513-529.
31. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
32. Newby JC, Johnston SR, Smith IE, et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 1997;3:1643-1651.
33. Normanno N, De Luca A, Maiello MR, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. Front Biosci. 2005;10:2611-2617.